BlackRock, Inc. Reduces Stake in Lifecore Biomedical, Inc. Below 5% Threshold

BlackRock, Inc. filed a Schedule 13G/A on April 27, 2026, disclosing a reduced stake in Lifecore Biomedical, Inc. (LFCR). As of the event date of March 31, 2026, BlackRock reported beneficial ownership of 1,867,916 shares of common stock, representing a 4.98% ownership interest in the company. This filing marks an amendment to a previous position, reflecting that BlackRock's ownership has fallen below the 5% threshold. According to the filing, BlackRock holds sole voting power over 1,844,413 shares and sole dispositive power over the full 1,867,916 shares. The shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. Various subsidiaries of BlackRock, Inc. are identified as having the right to receive dividends or proceeds from the sale of these securities. This reduction in holdings signifies that BlackRock is no longer a reporting person under the 5% ownership rule for Lifecore Biomedical, Inc. as of this reporting period.